Transforming Drug Discovery & Development
.jpg)
In-solution measurements of over 10 key biophysical parameters with a single technology, including molecular size, binding affinities, and interaction kinetics.
.png)
In-Solution Kinetics and Absolute Size
FIDA measures binding kinetics directly in solution, providing a more accurate representation of how molecules behave in their natural state, avoiding the cumbersome workflows of traditional surface-based techniques. The result is precise, easily interpretable, “artefact-free” data on binding affinities and kinetic rates that reflect actual biological conditions. Furthermore, by measuring the absolute size of molecules in solution, FIDA enables monitoring a range of integrity parameters, incl. conformational changes, oligomeric state and protein aggregation—three critical factors influencing drug efficacy and stability.
High Sensitivity Across Concentration Ranges
FIDA excels at measuring interactions across a wide concentration range (pM to mM), from small molecules to large biomolecules. This flexibility is crucial for drug discovery teams who need to test molecules at varying concentrations without losing sensitivity. Whether screening for early hits, optimizing lead compounds, or predicting drug developability, FIDA delivers the precision needed to confidently assess binding affinity, even in low-concentration samples.
Label-Free, Native State Analysis
Traditional methods often require the use of labels or modifications that can interfere with the natural properties of the drug target. With a wide array of detectors available, Fida can operate label-free, preserving the integrity of proteins and other biomolecules. This allows for more reliable data when investigating protein-ligand interactions, which is especially important in the development of biologics where maintaining the natural structure is key
.png)
Fida for Biologics
Biologics, such as monoclonal antibodies and therapeutic proteins, require detailed characterization to ensure structural integrity and efficacy throughout the drug development process. FIDA’s unique ability to measure the hydrodynamic radius (Rh), detect integrity in these large biomolecules allows researchers to monitor key factors like protein folding, aggregation, and binding affinity in real-time, under physiological conditions.
Key benefits for biologics:
Detection of critical conformational changes, oligomerization, and aggregation.
Wide dynamic range for analyzing large biomolecules and complexes.
Monitoring of binding affinity and stability in conditions close to biological environments.
Early investigation of drug developability without restrictions on the formulation buffers
Label-free, in-solution analysis that preserves natural protein structure.
FIDA for Small Molecule Drugs
For small molecule drugs, precise detection of binding affinities and kinetics is essential, especially in the early stages of development. FIDA excels at measuring these interactions even at low concentrations, providing accurate data on binding kinetics and affinity in complex mixtures. This capability is critical for identifying promising candidates in fragment-based drug discovery or optimizing lead compounds.
Key benefits for small molecules:
High sensitivity for detecting low-concentration interactions.
Accurate measurement of binding affinities in complex environments.
Supports a wide range of applications, from fragment-based screening to lead optimization.
Low sample requirements, ideal for early-stage discovery.
Addressing Key Drug Development Challenges
Reducing Attrition Rates: By providing 10 different readouts FIDA allows for fast, informed decision making. Plus, since first-principle affinity measurements accurately reflect binding dynamics, FIDA helps researchers select better candidates earlier in the process, thereby reducing costly late-stage failures.
Increasing transparency: FIDA’s delivers quality control/characterisation report for each sample measured, which helps ensure that drug candidates maintain the necessary biochemical properties throughout the development process. This comprehensive quality control can mitigate risks and prevent issues from emerging in clinical trials.
.jpg)
.jpg)
%20(1).jpg)
Make better-informed, faster decisions, from early discovery to clinical trials.
FIDA technology provides real-time, in-solution measurements of molecular interactions, offering drug developers unmatched precision and flexibility with only nanoliters of sample material. Whether you are focusing on biologics or small molecule drugs, FIDA enhances your ability to make faster, data-driven decisions across all stages of the drug development pipeline.
Take Your Drug Development Further
Whether you are advancing biologics or small molecule drugs, FIDA technology empowers your drug discovery efforts by delivering precise, actionable data that enhances decision-making and reduces risk throughout the development process. Contact us to learn more about how FIDA can optimize your drug pipeline.